Nanopharmaceuticals – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The global nanopharmaceuticals market size was US$27 billion in 2018 and is expected to grow at CAGR of more than 7% between 2018 and 2025. Nanomedicine is the application of nanotechnology for the diagnosis, prevention, and treatment of disease. It encompasses different applications including drug delivery systems, therapeutic use, imaging, diagnostics, biomaterials, and active implants.

The nanopharmaceuticals market research report will assist in developing business strategies by understanding how nanotechnology is being used in healthcare today and how this technology is expected to affect the healthcare sector in the future. The report will also help in identifying emerging industry trends to gain a competitive advantage.

Nanopharmaceuticals

For more insights on the nanopharmaceuticals market forecast, download a free report sample

Nanopharmaceuticals Market - Key Trends

The key trends that are impacting the nanopharmaceuticals market can be classified into three categories: technology trends, macroeconomic trends, and regulatory trends.

  • Technology Trends – The key technology trends impacting the nanopharmaceuticals market are the use of nanomaterials in personalized/ precision medicine, and as carriers for RNAi-based therapies, development of smart nanocarriers, and nano-radio enhancers. It also includes the increasing use of immunoconjugates in nanomedicine, use of theranostic nanoparticles in cancer, and new routes of administration among others.
  • Macroeconomic Trends – The key macroeconomic trends that will shape the nanopharmaceuticals market are the aging population and rise of chronic diseases, antibiotic resistance, reimbursement and cost-benefit considerations, government investment in nanomedicine and increasing M&A activities among others.
  • Regulatory Trends – The key regulatory trends impacting the nanopharmaceuticals market include the lack of specific regulatory guidelines for nanomedicines, and regulation of follow-on nano-pharmaceuticals.

Nanopharmaceuticals - Industry Analysis

The global nanopharmaceuticals market size was US$27 billion in 2018 and is expected to grow at a CAGR of more than 7% between 2018 and 2025. The polymer- and nanocrystal-based nanopharmaceuticals held the largest revenue share in 2018.

The analysis of the nanopharmaceuticals industry also covers:

  • Marketed nanopharmaceuticals
  • Pipeline nanopharmaceuticals
  • Mergers, acquisitions, and strategic alliances
  • Timeline
  • Case studies

Nanopharmaceuticals Market - Value Chain Analysis

The Nanopharmaceuticals industry value chain can be split into immunoconjugates, nanoparticles, and nanoemulsions.

Immunoconjugates: Immunoconjugates are targeted medicines that deliver a toxic payload to tumor cells via a linker attached to a mAb that binds to a specific target antigen expressed on cancer cells. The key layers under Immunoconjugates are Antibody-Drug Conjugates, Antibody-Radionuclide, and Antibody-Antibiotic.

Nanopharmaceuticals Market Value Chain Analysis

Nanopharmaceuticals Market Value Chain Analysis

To know more about the nanopharmaceuticals market value chain, download a free report sample

Leading Public Companies in the Nanopharmaceuticals Market

The leading public companies in the nanopharmaceuticals market are Actinium Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc., Amgen Inc, Aurinia Pharmaceuticals Inc, AstraZeneca, Bausch Health Companies Inc, Biogen, Ipsen SA, Merck & Co Inc, Pfizer Inc, and Sanofi among others.

The leading private companies in the nanopharmaceuticals market are Horizon Pharmaceuticals Inc, Janssen Pharmaceuticals Inc, Nanospectra Biosciences Inc, Ocugen Inc, Pharmacosmos AS, and Rakuten Medical Inc among others.

Nanopharmaceuticals Market Overview

Report Pages 96
Regions Covered Global
Market Size (2018) $27 billion
CAGR (2018-2025) >7%
Key Trends Technology Trends, Macroeconomic Trends, and Regulatory Trends
Value Chains Immunoconjugates, Nanoparticles, and Nanoemulsions
Leading Public Companies Actinium Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc., Amgen Inc, Aurinia Pharmaceuticals Inc, AstraZeneca, Bausch Health Companies Inc, Biogen, Ipsen SA, Merck & Co Inc, Pfizer Inc, and Sanofi
Leading Private Companies Horizon Pharmaceuticals Inc, Janssen Pharmaceuticals Inc, Nanospectra Biosciences Inc, Ocugen Inc, Pharmacosmos AS, and Rakuten Medical Inc

Key Highlights

The Nanopharmaceuticals report provides an assessment of the key industry trends impacting how nanopharmaceuticals are being used in healthcare today, including technological, regulatory, and macroeconomic themes.

Components of the report include:

  • Key Industry Players – the big players in the nanopharmaceuticals industry and where they sit in the value chain.
  • Trends in the nanopharmaceuticals space – key trends impacting the use of nanopharmaceuticals classified into technology, macroeconomic, and regulatory themes.
  • Industry Analysis – the market value of marketed and pipeline nanopharmaceuticals to 2025, as well as a breakdown of nanopharmaceuticals by branded or generic product, phase of development, type of company, and route of administration. Key M&A and licensing agreements in the nanopharmaceuticals space are also included, as well as case studies showing examples of the different types of nanopharmaceuticals and their application.
  • Value Chain – Leaders and challengers by nanopharmaceuticals type

Reasons to Buy

The report will help you to:

  • Develop business strategies by understanding how nanotechnology is being used in healthcare today and how this technology is expected to affect the healthcare sector in the future.
  • Stay up to date on the industry’s big players in nanopharmaceuticals and where they sit in the value chain.
  • Identify emerging industry trends to gain a competitive advantage.
  • Identify pipeline targets for M&A and licensing opportunities.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Industry Players

3 Industry Trends

3.1 Technology Trends

3.2 Macroeconomic Trends

3.3 Regulatory Trends

3.4 Expected Impact of Nanomedicines on the Biopharmaceutical Industry in 2020

4 Industry Analysis

4.1 Market Size and Growth Forecasts

4.2 Marketed Nanopharmaceuticals

4.3 Pipeline Nanopharmaceuticals

4.4 Mergers, Acquisitions, and Strategic Alliances

4.5 Timeline

4.6 Case Studies

4.6.1 Targeting Liver Cells with Diasome’s Liposomal Additive Improves the Efficacy and Safety of Insulins

4.6.2 PharmaCyte’s Polymer-Based Cell-in-a-Box Technology Allows the Administration of Lower Doses of Chemotherapy

4.6.3 Kala Pharmaceuticals’ Nanocrystal-Based AMPPLIFY Technology Allows Drug Particles to Penetrate Mucus Barriers and Significantly Increase Drug Delivery to Target Eye Tissues

4.6.4 Celgene’s Abraxane, an Albumin-Bound Nanoformulation of Paclitaxel, Reduces the Toxicity Associated with Its Free Form

4.6.5 Oasmia Pharmaceuticals’ XR17 Micelle Technology Allows for Shorter Infusions of Chemotherapy with No Premedication Required

4.6.6 Alnylam’s Onpattro, Based on Lipid Nanotechnology, Is the First RNAi Therapeutic to Receive Approval

4.6.7 Starpharma’s Dendrimer-Based DEP Technology Improves Efficacy and Reduces Toxicity Associated with Leading Chemotherapy Drugs

4.6.8 Nanobiotix’s Hensify, a First-in-Class Radioenhancer, Utilizes Inorganic Hafnium Oxide Nanoparticles to Amplify the Effects of Radiation Treatment

4.6.9 Daiichi Sankyo’s Antibody-Drug Conjugate Enhertu Offers a Novel Treatment Option for Metastatic Breast Cancer

5 Value Chain

5.1 Nanoparticles

5.1.1 Liposomal Nanoparticles

5.1.2 Polymeric Nanoparticles

5.1.3 Nanocrystals

5.1.4 Protein Nanoparticles

5.1.5 Lipid Nanoparticles

5.1.6 Micelles

5.1.7 Dendrimers

5.1.8 Inorganic Nanoparticles

5.1.9 Immunoconjugates

5.1.10 Nanoemulsions

6 Companies

6.1 Public Companies

6.2 Private Companies

7 Abbreviations

8 Appendix

8.1 Bibliography

8.2 Traditional Thematic Research Does a Poor Job of Picking Winners and Losers

8.3 Introducing GlobalData’s Thematic Engine

8.4 This Is How It Works

8.5 How Our Research Reports Fit into Our Overall Research Methodology

8.6 About GlobalData

8.7 About the Authors

8.7.1 Healthcare Analyst

8.8 Director of Thematic Research

8.8.1 Director of Thematic Analysis

8.9 Senior Director of Market Research

8.10 Global Head and EVP of Healthcare Operations and Strategy

8.11 Contact Us

8.12 Disclaimer

Frequently asked questions

Nanopharmaceuticals – Thematic Research thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Nanopharmaceuticals – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nanopharmaceuticals – Thematic Research in real time.

  • Access a live Nanopharmaceuticals – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.